289 related articles for article (PubMed ID: 15461572)
1. Cytokine gene therapy for malignant glioma.
Okada H; Pollack IF
Expert Opin Biol Ther; 2004 Oct; 4(10):1609-20. PubMed ID: 15461572
[TBL] [Abstract][Full Text] [Related]
2. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
[TBL] [Abstract][Full Text] [Related]
3. Cell therapies in neuro-oncology.
Pellegatta S; Finocchiaro G
Neurol Sci; 2005 May; 26 Suppl 1():S43-5. PubMed ID: 15883693
[TBL] [Abstract][Full Text] [Related]
4. Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells.
Okada H; Villa L; Attanucci J; Erff M; Fellows WK; Lotze MT; Pollack IF; Chambers WH
Gene Ther; 2001 Aug; 8(15):1157-66. PubMed ID: 11509946
[TBL] [Abstract][Full Text] [Related]
5. [Immunotherapy in brain tumors].
De Carli E; Delion M; Rousseau A
Ann Pathol; 2017 Feb; 37(1):117-126. PubMed ID: 28111040
[TBL] [Abstract][Full Text] [Related]
6. Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.
Mineharu Y; King GD; Muhammad AK; Bannykh S; Kroeger KM; Liu C; Lowenstein PR; Castro MG
Clin Cancer Res; 2011 Jul; 17(14):4705-18. PubMed ID: 21632862
[TBL] [Abstract][Full Text] [Related]
7. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial.
Yamanaka R; Abe T; Yajima N; Tsuchiya N; Homma J; Kobayashi T; Narita M; Takahashi M; Tanaka R
Br J Cancer; 2003 Oct; 89(7):1172-9. PubMed ID: 14520441
[TBL] [Abstract][Full Text] [Related]
8. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens.
Liau LM; Black KL; Prins RM; Sykes SN; DiPatre PL; Cloughesy TF; Becker DP; Bronstein JM
J Neurosurg; 1999 Jun; 90(6):1115-24. PubMed ID: 10350260
[TBL] [Abstract][Full Text] [Related]
9. Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways.
Kuwashima N; Nishimura F; Eguchi J; Sato H; Hatano M; Tsugawa T; Sakaida T; Dusak JE; Fellows-Mayle WK; Papworth GD; Watkins SC; Gambotto A; Pollack IF; Storkus WJ; Okada H
J Immunol; 2005 Aug; 175(4):2730-40. PubMed ID: 16081851
[TBL] [Abstract][Full Text] [Related]
10. Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.
Lowenstein PR; Castro MG
Clin Immunol; 2018 Apr; 189():43-51. PubMed ID: 28720549
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cell-based immunotherapy of malignant gliomas.
Parajuli P; Sloan AE
Cancer Invest; 2004; 22(3):405-16. PubMed ID: 15493362
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell vaccines.
Yamanaka R; Kajiwara K
Adv Exp Med Biol; 2012; 746():187-200. PubMed ID: 22639169
[TBL] [Abstract][Full Text] [Related]
13. Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
Batich KA; Swartz AM; Sampson JH
Expert Opin Biol Ther; 2015 Jan; 15(1):79-94. PubMed ID: 25327832
[TBL] [Abstract][Full Text] [Related]
14. An experimental study of dendritic cells-mediated immunotherapy against intracranial gliomas in rats.
Zhu X; Lu C; Xiao B; Qiao J; Sun Y
J Neurooncol; 2005 Aug; 74(1):9-17. PubMed ID: 16078102
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model.
Mineharu Y; Muhammad AK; Yagiz K; Candolfi M; Kroeger KM; Xiong W; Puntel M; Liu C; Levy E; Lugo C; Kocharian A; Allison JP; Curran MA; Lowenstein PR; Castro MG
Neurotherapeutics; 2012 Oct; 9(4):827-43. PubMed ID: 22996231
[TBL] [Abstract][Full Text] [Related]
16. T cell immunity in patients with malignant glioma: recent progress in dendritic cell-based immunotherapeutic approaches.
Akasaki Y; Black KL; Yu JS
Front Biosci; 2005 Sep; 10():2908-21. PubMed ID: 15970545
[TBL] [Abstract][Full Text] [Related]
17. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas.
Okada H; Lieberman FS; Walter KA; Lunsford LD; Kondziolka DS; Bejjani GK; Hamilton RL; Torres-Trejo A; Kalinski P; Cai Q; Mabold JL; Edington HD; Butterfield LH; Whiteside TL; Potter DM; Schold SC; Pollack IF
J Transl Med; 2007 Dec; 5():67. PubMed ID: 18093335
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell vaccines and immunity in glioma patients.
Wheeler CJ; Black KL
Front Biosci; 2005 Sep; 10():2861-81. PubMed ID: 15970541
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell based vaccination strategy: an evolving paradigm.
Filley AC; Dey M
J Neurooncol; 2017 Jun; 133(2):223-235. PubMed ID: 28434112
[TBL] [Abstract][Full Text] [Related]
20. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report.
Liau LM; Black KL; Martin NA; Sykes SN; Bronstein JM; Jouben-Steele L; Mischel PS; Belldegrun A; Cloughesy TF
Neurosurg Focus; 2000 Dec; 9(6):e8. PubMed ID: 16817691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
